Table 1.
Generation of leukotrienes and pathway intermediates in BMMC derived from BALB/c, cPLA2+/+, and cPLA2−/− mice
| Stimulus | Product | BMMC
|
||
|---|---|---|---|---|
| BALB/c (n = 5) | cPLA2+/+ (n = 3) | cPLA2−/−(n = 3)* | ||
| IgE/Ag | LTC4 | 16.4 ± 4.0 | 73.6 ± 4.0 | 0 |
| LTB4 | 8.0 ± 2.8 | 17.0 ± 2.3 | 0 | |
| 5-HETE | 8.7 ± 3.0 | 34.4 ± 2.0 | 0 | |
| 6-t-LTB4 | 5.0 ± 2.9 | 30.6 ± 3.2 | 0 | |
| SCF | LTC4 | 11.6 ± 4.8 | 14.5 ± 0.7 | 0 |
| LTB4 | 7.0 ± 1.9 | 11.3 ± 1.0 | 0 | |
| 5-HETE | 9.0 ± 3.5 | 1.9 ± .01 | 0 | |
| 6-t-LTB4 | 4.7 ± 2.6 | 3.7 ± 1.7 | 0 | |
Leukotriene (LT) pathway products (ng per 106 cells) were measured by using RP-HPLC in supernatants of BMMC sensitized with IgE anti-TNP and activated with 100 ng/ml TNP-BSA (IgE/Ag) or with 100 ng/ml SCF. 5-HETE, 5-hydroxyeicosatetraenoic acid; 6-t-LTB4, 6-trans-LTB4 diastereoisomers. ∗, P < 0.01 compared to total leukotriene generation from cPLA2+/+ BMMC for both agonists.